Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.

Abstract: A process for producing solid dosage forms by mixing at least one polymer binder, at least one active ingredient and, where appropriate, conventional additives to form a plastic mixture, and shaping, wherein a physiologically tolerated, water-swellable graft copolymer or a mixture of graft copolymers is employed as polymeric binder.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Abstract: A solid or semisolid, at least two-phase active ingredient-containing formulation in which there is multiparticulate incorporation of one of the two phases into a matrix of the other phase, and at least one of the phases contains at least one active ingredient, obtainable by introducing particles of one phase into the other phase in a plastic state, and shaping the material while still plastic.

Abstract: A solid dosage form for application in the oral cavity, comprising a poorly bioavailable pharmaceutical active ingredient dispersed in a pharmaceutically acceptable matrix.

Abstract: A process for producing solid creatine-containing dosage forms, wherein a) a mixture which comprises at least one thermoplastic, physiologically tolerated, water-soluble or water-swellable polymeric binder and creatine, and contains 1 to 20 mol of water per mol of creatine is prepared, b) the mixture is plasticated at or above the softening point of the polymeric binder, preferably with at least partial evaporation of the water, c) the plasticated mixture is shaped to dosage forms and cooled.

Abstract: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.

Abstract: A process for producing pellets comprising biologically active substances in which the biologically active substances are homogeneously dispersed in a matrix based on at least one thermoplastic polymer, which polymer has in aqueous medium a pH-dependent solubility, by homogeneous mixing of the starting materials in the melt and subsequent extrusion and shaping, which comprises the shaping being performed in a cooling medium in which the pellets are not soluble or dispersible.

Abstract: The present invention relates to mechanically stable pharmaceutical presentations for oral administration, comprising in addition to one or more active ingredients and at least one melt-processable matrix-forming excipient more than 10 and up to 40% by weight of a surface-active substance with an HLB of from 2 to 18, which is liquid at 20° C. or has a drop point in the range from 20 to 50° C.

Abstract: Solid dosage forms are obtained by mixing at least one polymeric binder, at least one active ingredient, and, where appropriate, conventional additives to form a plastic mixture, and shaping, using as polymeric binder a copolymer of an N-vinyllactam and a copolymerizable monomer having a hydrophobic radical. Dosage forms which show slow release of the active ingredient are obtained in a simple and low-cost manner.

Abstract: The invention relates to the use of copolymers comprising a) 82 to 99.9 mol % of at least one monoethylenically unsaturated C3-C8-carboxylic acid; b) 0.1 to 18 mol % of at least one monomer selected from the group b1) N—C8-C30-alkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids, b2) N,N—C8-C30-dialkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids, b3) C8-C30-alkyl esters of monoethylenically unsaturated C3-C8-carboxylic acids; c) 0 to 17.9 mol % of at least one monomer selected from the group of c1) vinyl esters of aliphatic C8-C30-carboxylic acids, c2) C8-C30-alkylvinyl ethers, the mol % data for the individual components adding up to 100%, as solubilizer.

Abstract: The invention relates to the use of copolymers comprising

Abstract: The invention relates to the use of copolymers comprising a) 82 to 99.9 mol % of at least one monoethylenically unsaturated C3-C8-carboxylic acid; b) 0.1 to 18 mol % of at least one monomer selected from the group b1) N—C8-C30-alkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids, b2) N,N—C8-C30-dialkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids, b3) C8-C30-alkyl esters of monoethylenically unsaturated C3-C8-carboxylic acids; c) 0 to 17.9 mol % of at least one monomer selected from the group of c1) vinyl esters of aliphatic C8-C30-carboxylic acids, c2) C8-C30-alkylvinyl ethers, mol % data for the individual components adding up to 100%, as solubilizer.

Abstract: A fast-acting analgesic comprises as analgesic substance ibuprofen in an adjuvant matrix with a porous structure and a density of greater than 1 and up to 2.5 g/cm3.

Abstract: A process for producing solid creatine-containing dosage forms, wherein

Abstract: The present invention relates to a solid dosage form comprising at least one polymeric binder and at least one active ingredient and, where appropriate, conventional additives, wherein the polymeric binder consists of copolymerized units a) 15-83% by weight of at least one N-vinyllactam, b) 15-83% by weight of methyl methacrylate, c) 2-70% by weight of at least one other monomer and d) 0-9.9% by weight of at least one &agr;,&bgr;-ethylenically unsaturated acid.

Abstract: The use of copolymers ofA) 60-99 mol % of N-vinylpyrrolidone, andB) 1-40 mol % of a monomer selected from the group ofb1) C.sub.8 -C.sub.30 -alkyl esters of monoethylenically unsaturated C.sub.3 -C.sub.8 -carboxylic acids,b2) N-alkyl- or N,N-dialkyl-substituted amides of acrylic acid or of methacrylic acid with C.sub.8 -C.sub.18 -alkyl radicals, orb3) vinyl esters of aliphatic C.sub.8 -C.sub.30 -carboxylic acids, or mixtures of these monomers,as surface-active substances in preparations of water-insoluble substances.